• Revenue up 48.6% to $7.29 million
• Loss down 24.3% to $5.25 million
• Cash position at $2.83 million

Immuron Limited has released its preliminary final report for the year ended 30 June 2025. The company reported revenue from contracts with customers of $7,287,002, which is an increase of 48.6% from the prior financial year (2024: $4,902,865), primarily due to the sales increase in the Australian and North American markets for Travelan®. The reported loss after tax of the current financial year was $5,253,209, down 24.3% from the previous year (2024: $6,936,957). The loss was after fully expensing the company's research and development expenditure of $3,597,296 incurred during the year (2024: $5,375,461), of which $146,252 (2024: $2,599,458) was funded by the R&D grant from Medical Technology Enterprise Consortium (MTEC). As at 30 June 2025, the company's cash position was $2,830,526 (30 June 2024: $11,657,315). The company had trade and other receivables of $1,888,370 (30 June 2024: $1,387,573), which includes future receivables from the Australian Government under the R&D Tax Incentive program. The preliminary final report will be followed by the audited financial statements to be released by 30 September 2025.